Seqirus’ adjuvanted quadrivalent flu vaccine shows better protection for young children
admin 12th September 2017 Uncategorised 0Seqirus already has the first and only FDA-approved cell-based flu vaccine, Flucelvax, for those four years and older. Now, aiming at a younger population, the CSL subsidiary has returned with phase 3 data that shows an adjuvanted quadrivalent flu shot could be a better choice than non-adjuvanted options for those younger than two.
More: Seqirus’ adjuvanted quadrivalent flu vaccine shows better protection for young children
Source: fierce